AUS
NZ
UK
CA
USA
IND
Healthcare
PureTech Health Seaport listing lifts FTSE 350 sentiment surge?
May 01, 2026 09:36 AM BST| By Vivek SinghPureTech Health linked Seaport Therapeutics listing activity reflects FTSE 350 biotechnology segment trends, focusing on entity development and evolving equity structure dynamics.
Is Intl Biotechnology Trust Gaining on FTSE 350 Deal Momentum?
April 30, 2026 07:39 PM BST| By Vivek SinghInternational Biotechnology Trust reflects biotech sector evolution in the FTSE 350, driven by acquisitions, clinical progress, and growing reliance on innovative therapeutic development worldwide today.
AstraZeneca Outlook Strengthens on Pipeline Momentum
April 30, 2026 12:54 PM BST| By Vivek SinghHighlights,Earnings outlook improves on recent performance,Pipeline catalysts attract strong attention,Clinical progress supports long-term visibility,AstraZeneca’s latest outlook reflects improved earnings expectations and steady clinical pipeline m...
FTSE 100 Pharma Giants Defy Policy Pressures With Strong Start
April 29, 2026 11:48 AM BST| By Team Kalkine MediaPharmaceutical companies demonstrate resilience through strong earnings and innovation, while global pricing policies introduce uncertainty, shaping strategic direction and long-term growth across the healthcare sector.
Advanced Medical Solutions Gains Attention Amid FTSE Takeover Talks
April 29, 2026 11:44 AM BST| By Team Kalkine MediaAdvanced Medical Solutions (LSE:AMS) gains focus following takeover discussions, highlighting its role within specialised healthcare markets and its position across key UK AIM indices.
FTSE 100 Pharma Strength As AstraZeneca Drives Momentum
April 29, 2026 10:26 AM BST| By Vivek SinghHealthcare sector strength, led by AstraZeneca, reflects stability and innovation within the FTSE market, highlighting the role of pharmaceutical companies in shaping UK equity performance.
FTSE 100 Healthcare Strength As GSK Drives Market Momentum
April 29, 2026 10:06 AM BST| By Vivek SinghHealthcare sector strength, led by pharmaceutical companies, continues to shape FTSE performance, reflecting stability and innovation within the UK equity market.
FTSE 350: Is Genflow Drawing Interest After Canine Gene Data?
April 28, 2026 02:07 PM BST| By Vivek SinghGenflow Biosciences broadens collaboration efforts in the FTSE 350, highlighting growing interest in canine gene therapy research and continued progress in ageing-related biotechnology studies.
AOTI Strengthens on Wound Therapy Outcomes
April 27, 2026 05:52 PM BST| By Vivek SinghHighlights,Wound oxygen therapy shows strong clinical outcomes in chronic care,Real-world study highlights improved healing in complex wound cases,Reduced complications observed compared with conventional treatment approaches,AOTI shares moved higher...
FTSE 350 GSK PLC Oncology Court Ruling Drives Legal Case Progress?
April 27, 2026 02:31 PM BST| By Vivek SinghGSK PLC within the FTSE 350 reflects ongoing legal proceedings, oncology portfolio expansion, and pharmaceutical sector activity centred on dostarlimab development and licensing frameworks.
AstraZeneca PLC FTSE 100 reacts to partner review delay results?
April 27, 2026 02:31 PM BST| By Vivek SinghAstraZeneca activity in the FTSE 100 highlights oncology partnerships, manufacturing adjustments, and structured collaboration within global pharmaceutical development and supply chain systems.
AstraZeneca Outlook Steady Amid Daiichi Review Update
April 27, 2026 12:18 PM BST| By Vivek SinghAstraZeneca outlook remains steady after Daiichi Sankyo supply review update, with oncology partnerships continuing smoothly and market interpretation pointing to operational adjustments without disruption to core pharmaceutical collaboration.
Does GSK’s FTSE 100 Standing Shift After Court Claim Dismissal?
April 27, 2026 11:46 AM BST| By Vivek SinghGSK’s FTSE 100 presence reflects ongoing legal and clinical developments, including a narrowed dispute over a cancer drug licence and continued research into oncology treatments.
FTSE Megatrends: Where Future Market Leaders Begin
April 24, 2026 01:30 PM BST| By Team Kalkine MediaMegatrends are reshaping global markets, offering insights into future leaders. Understanding thematic strategies, stock selection, and index performance is key to navigating long-term growth opportunities effectively.
AstraZeneca Advances Kidney Care With Ultomiris Breakthrough
April 22, 2026 05:53 PM BST| By Vivek SinghHighlights,Ultomiris shows strong progress in rare kidney condition study,Early signs indicate reduced kidney stress markers,Regulatory pathway discussions expected in key regions,AstraZeneca’s latest study highlights encouraging progress for a rare...
AstraZeneca Advances Kidney Care with Ultomiris Trial Success
April 21, 2026 08:52 PM BST| By Vivek SinghAstraZeneca reports encouraging trial progress for Ultomiris in rare kidney disease, supporting future regulatory submissions and expanding focus within the LSE & FTSE stock market landscape.
Hemogenyx Insider Activity Signals Long-Term Confidence
April 21, 2026 08:20 PM BST| By Vivek SinghInsider activity at Hemogenyx Pharmaceuticals highlights confidence, strong ownership alignment, and evolving trends within the UK equity market.
What is driving Sectra momentum?
April 21, 2026 05:00 PM BST| By Team Kalkine MediaSectra cloud agreement highlights healthcare technology expansion, collaborative NHS initiatives, and the growing role of digital imaging platforms shaping connected clinical environments across modern healthcare systems.
London Stocks Mixed as Pharma and Defence Weigh
April 21, 2026 01:07 PM BST| By Vivek SinghHighlights,London equities show mixed direction amid global cues,Defence and pharmaceutical names face selling pressure,Real estate and consumer sectors provide selective support,London equity markets have reflected a mixed tone as global macroeconom...
AstraZeneca Drug Advances Spark Strong Market Attention
April 21, 2026 12:25 PM BST| By Vivek SinghHighlights,Late-stage trials reinforce confidence in respiratory therapy,Expanded patient scope opens wider commercial pathway,Market outlook aligns with strong long-term revenue expectations,AstraZeneca’s latest clinical progress in respiratory trea...
